Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF
- PMID: 16266992
- DOI: 10.1158/0008-5472.CAN-05-1683
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF
Abstract
The protein kinase B-RAF is mutated in approximately 8% of human cancers. Here we show that presumptive mutants of the closely related kinase, C-RAF, were detected in only 4 of 545 (0.7%) cancer cell lines. The activity of two of the mutated proteins is not significantly different from that of wild-type C-RAF and these variants may represent rare human polymorphisms. The basal and B-RAF-stimulated kinase activities of a third variant are unaltered but its activation by RAS is significantly reduced, suggesting that it may act in a dominant-negative manner to modulate pathway signaling. The fourth variant has elevated basal kinase activity and is hypersensitive to activation by RAS but does not transform mammalian cells. Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene. This lack of activation occurs because C-RAF lacks a constitutive charge within a motif in the kinase domain called the N-region. This fundamental difference in RAF isoform regulation explains why B-RAF is frequently mutated in cancer whereas C-RAF mutations are rare.
Similar articles
-
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.Cancer Res. 2003 Dec 1;63(23):8132-7. Cancer Res. 2003. PMID: 14678966
-
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).Mol Cell. 2009 Nov 13;36(3):477-86. doi: 10.1016/j.molcel.2009.10.017. Mol Cell. 2009. PMID: 19917255
-
Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.Cancer Res. 2006 Apr 1;66(7):3401-8. doi: 10.1158/0008-5472.CAN-05-0115. Cancer Res. 2006. PMID: 16585161
-
RAF protein-serine/threonine kinases: structure and regulation.Biochem Biophys Res Commun. 2010 Aug 27;399(3):313-7. doi: 10.1016/j.bbrc.2010.07.092. Epub 2010 Jul 30. Biochem Biophys Res Commun. 2010. PMID: 20674547 Review.
-
Raf: a strategic target for therapeutic development against cancer.J Clin Oncol. 2005 Sep 20;23(27):6771-90. doi: 10.1200/JCO.2005.08.036. J Clin Oncol. 2005. PMID: 16170185 Review.
Cited by
-
Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.Mol Cancer. 2023 Dec 18;22(1):208. doi: 10.1186/s12943-023-01903-x. Mol Cancer. 2023. PMID: 38111008 Free PMC article. Review.
-
Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation.Angew Chem Int Ed Engl. 2016 Jan 18;55(3):983-6. doi: 10.1002/anie.201509272. Epub 2015 Dec 8. Angew Chem Int Ed Engl. 2016. PMID: 26644280 Free PMC article.
-
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer.Front Pharmacol. 2021 Nov 15;12:772510. doi: 10.3389/fphar.2021.772510. eCollection 2021. Front Pharmacol. 2021. PMID: 34867402 Free PMC article. Review.
-
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer.Front Cell Dev Biol. 2016 Apr 27;4:33. doi: 10.3389/fcell.2016.00033. eCollection 2016. Front Cell Dev Biol. 2016. PMID: 27200346 Free PMC article. Review.
-
MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions.Int J Mol Sci. 2025 Jul 17;26(14):6875. doi: 10.3390/ijms26146875. Int J Mol Sci. 2025. PMID: 40725122 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous